Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series.
- Author:
Ji Wan LEE
1
;
Charles J CHO
;
Do Hoon KIM
;
Ji Yong AHN
;
Jeong Hoon LEE
;
Kee Don CHOI
;
Ho June SONG
;
Sook Ryun PARK
;
Hyun Joo LEE
;
Yong Hee KIM
;
Gin Hyug LEE
;
Hwoon Yong JUNG
;
Sung Bae KIM
;
Jong Hoon KIM
;
Seung Il PARK
Author Information
- Publication Type:Original Article
- Keywords: Esophageal carcinoma; Endoscopic resection; Survival; Recurrence
- MeSH: Esophageal Neoplasms*; Follow-Up Studies; Humans; Incidence; Pathology; Recurrence*; Survival Rate
- From:Clinical Endoscopy 2018;51(5):470-477
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: To report the long-term survival and tumor recurrence outcomes in patients with superficial esophageal cancer (SEC) after complete non-curative endoscopic resection (ER). METHODS: We retrieved ER data for 24 patients with non-curatively resected SEC. Non-curative resection was defined as the presence of submucosal and/or lymphovascular invasion on ER pathology. Relevant clinical and tumor-specific parameters were reviewed. RESULTS: The mean age of the 24 study patients was 66.3±8.3 years. Ten patients were closely followed up without treatment, while 14 received additional treatment. During a mean follow-up of 59.0±33.2 months, the 3- and 5-year survival rates of all cases were 90.7% and 77.6%, respectively. The 5-year overall survival rates were 72.9% in the close observation group and 82.1% in the additional treatment group (p=0.958). The 5-year cumulative incidences of all cases of recurrence (25.0% vs. 43.3%, p=0.388), primary EC recurrence (10.0% vs. 16.4%, p=0.558), and metachronous EC recurrence (16.7% vs. 26.7%, p=0.667) were similar between the two groups. CONCLUSIONS: Patients with non-curatively resected SEC showed good long-term survival outcomes. Given the similar oncologic outcomes, close observation may be an option with appropriate caution taken for patients who are medically unfit to receive additional therapy.
